BiotechTube

Dexycu

Phase 3Withdrawn
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cataract

Conditions

Cataract

Trial Timeline

Sep 1, 2022 → Sep 1, 2023

NCT ID
NCT05550350

About Dexycu

Dexycu is a phase 3 stage product being developed by EyePoint Pharmaceuticals for Cataract. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05550350. Target conditions include Cataract.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT05550350Phase 3Withdrawn
NCT05550363Phase 3Withdrawn

Competing Products

20 competing products in Cataract

See all competitors
ProductCompanyStageHype Score
ISV-305Sun PharmaceuticalPhase 3
77
ISV-303 + Bromday™Sun PharmaceuticalPhase 2
52
ISV-305Sun PharmaceuticalPhase 3
77
DE-108 + Levofloxacin 0.5%Santen PharmaceuticalPhase 3
77
Prednisolone acetateNovartisApproved
85
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
80
Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved
80
Dextenza Ophthalmic Insert + Prednisolone acetate ophthalmic suspension USP 1%Ocular TherapeutixPhase 3
72
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]Ocular TherapeutixPhase 2/3
60
Dexamethasone 0.4 MG [Dextenza]Ocular TherapeutixApproved
80
Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetateOcular TherapeutixApproved
80
Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic EmulsionOcular TherapeutixApproved
80
Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)EyePoint PharmaceuticalsApproved
80
DexycuEyePoint PharmaceuticalsPhase 3
72
DEXYCU (dexamethasone intraocular suspension) 9%.EyePoint PharmaceuticalsPre-clinical
18
Dexamethasone + Prednisolone Acetate OphthalmicEyePoint PharmaceuticalsApproved
80
Bimatoprost Implant System (High Dose) + Bimatoprost Implant System (Low Dose) + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 1/2
36
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
72
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
72
OMS302 + OMS302-PE + VehicleOmeros CorporationPhase 1/2
36

Other Products from EyePoint Pharmaceuticals

Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)Approved
80
Dexamethasone + Prednisolone Acetate OphthalmicApproved
80
FAI insert + Sham injectionPhase 3
72
Sham Injector + FAI InsertPhase 3
72
DexycuPhase 3
72